Table 2 Summary of the results on the long-term efficacy of RFA versus HR in the treatment of small HCCs
Outcome | No. studies | No. patients | RFA | HR | Odds Ratio [95% CI] | Z test (P-value) | I2 | Q test (P-value) | Egger's test (P-value) |
|---|---|---|---|---|---|---|---|---|---|
≤5 cm | |||||||||
Overall survival rate | |||||||||
3-year | 31 | 16,103 | 78.6% | 83.9% | 0.65 [0.53, 0.80] | <0.001 | 61% | <0.001 | 0.43 |
5-year | 20 | 14,665 | 60.8% | 71.4% | 0.57 [0.48, 0.67] | <0.001 | 42% | 0.03 | 0.51 |
Disease-free survival rate | |||||||||
3-year | 27 | 15,524 | 41.1% | 56.7% | 0.50 [0.41, 0.61] | <0.001 | 72% | <0.001 | 0.42 |
5-year | 20 | 14,640 | 26.6% | 37.8% | 0.47 [0.35, 0.65] | <0.001 | 84% | <0.001 | 0.08 |
≤3 cm | |||||||||
Overall survival rate | |||||||||
3-year | 19 | 13,298 | 81.2% | 85.7% | 0.62 [0.43, 0.89] | 0.009 | 64% | <0.001 | 0.35 |
5-year | 16 | 13,075 | 61.8% | 71.9% | 0.55 [0.42, 0.72] | <0.001 | 56% | 0.003 | 0.36 |
Disease-free survival rate | |||||||||
3-year | 16 | 13,109 | 42.5% | 57.2% | 0.52 [0.39, 0.70] | <0.001 | 74% | <0.001 | 0.58 |
5-year | 15 | 12,912 | 27.8% | 37.3% | 0.57 [0.38, 0.87] | 0.01 | 85% | <0.001 | 0.48 |
≤2 cm | |||||||||
Overall survival rate | |||||||||
3-year | 4 | 442 | 80.6% | 83.7% | 0.54 [0.12, 2.37] | 0.41 | 81% | 0.001 | 0.27 |
5-year | 4 | 442 | 69.0% | 74.2% | 0.65 [0.27, 1.55] | 0.33 | 67% | 0.03 | 0.58 |
Disease-free survival rate | |||||||||
3-year | 4 | 442 | 52.4% | 53.7% | 1.00 [0.47, 2.15] | 0.99 | 72% | 0.01 | 0.99 |
5-year | 4 | 442 | 42.5% | 41.6% | 1.08 [0.56, 2.11] | 0.81 | 61% | 0.05 | 0.60 |
